Skip to Content

Colon or Rectal Cancer, Stage I-III, Financial Burden Assessment (EAQ162CD)

Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent



This research trial studies the financial burden in patients with stage I-III colon or rectal cancer who are undergoing treatment. Collecting data from patients about their cost and quality of life may help doctors to better understand the impact of cancer treatment on a patient?s employment and finances.

Key Inclusion Criteria

Inclusion Criteria:

  • Patients must have a life expectancy of >= 24 months
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3
  • Patients must have a newly diagnosed colon or rectal cancer (initial diagnosis, either a biopsy or curative surgery, whichever is most recent) within 60 days of registration and have not yet received radiation or chemotherapy
  • Patients must have stage I, II, or III disease at the time of enrollment and will be treated with curative-intent; this can be defined either clinically or pathologically if they have already undergone surgery; for staging of both colon and rectal cancer, the definition of stage I-III is based on the seventh edition (2010) or an updated version of the tumor, node, metastasis (TNM) staging system
  • Patients are not eligible if they are already enrolled on a treatment clinical trial at the time of registration; they can remain on the study if they subsequently enroll on a treatment clinical trial during the study time period
  • Patients who choose to not receive radiation and/or chemotherapy after a curative-intent surgery are eligible to participate
  • Patients with a history of previous malignancy (except non-melanoma skin or cervical in-situ cancer) treated (with either surgery, chemotherapy, and/or radiation) within the last 3 years are not eligible
  • Patients must be able to complete questionnaires in English
  • Patients must sign and give written informed consent in accordance with institutional and federal guidelines

Phase: Observational

Learn More


IRB Protocol Number
Principal Investigator(s)
Michael Humeniuk, M.D.

Clinical Trial Categories

  • Cancer Care Delivery Research (CCDR)
  • Oncology
  • Gastrointestinal Cancer
ECOG-ACRIN Cancer Research Group
Abdelmohsen Alqalam at 864-560-1056
How to Participate

Abedelmohsen Alqalam

Was this page helpful?


Thank you for your feedback!

Thank you for your feedback and helping us to improve our website.
There will be no additional response.

News & Highlights

Stay Connected!

Get the latest news on the health topics that matter most to you.

Sign up